Amylovis-201 enhances physiological memory formation and rescues memory and hippocampal cell loss in a streptozotocin-induced Alzheimer's disease animal model

[Display omitted] •Amylovis-201 10 min but not 5 h after training prolongs memory duration in healthy rats.•Amylovis-201 administration to STZ rats reduces hippocampus dentate gyrus cells loss.•Amylovis-201 admiration to STZ rats improves spatial memory,•Amylovis-201 is a good candidate for the ther...

Full description

Saved in:

Bibliographic Details
Published in:	Brain research Vol. 1831; p. 148848
Main Authors:	Mercerón-Martínez, Daymara, Alacán Ricardo, Laura, Bejerano Pina, Arturo, Orama Rojo, Norma, Expósito Seco, Ariel, Vega Hurtado, Yamilé, Estupiñán Días, Bárbara, Fernández, Isabel, García Pupo, Laura, Sablón Carrazana, Marquiza, Rodríguez-Tanty, Chryslaine, Menéndez Soto del Valle, Roberto, Almaguer-Melian, William
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15-05-2024
Subjects:	Alzheimer Disease Alzheimer’s disease Animals Disease Models, Animal Functional recovery Hippocampus - metabolism Learning and memory Maze Learning Memory consolidation and Amylovis-201 Memory Disorders - metabolism Neurodegenerative Diseases - metabolism Spatial Memory Streptozocin - pharmacology Learning and memory Functional recovery Memory consolidation and Amylovis-201 Alzheimer’s disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[Display omitted] •Amylovis-201 10 min but not 5 h after training prolongs memory duration in healthy rats.•Amylovis-201 administration to STZ rats reduces hippocampus dentate gyrus cells loss.•Amylovis-201 admiration to STZ rats improves spatial memory,•Amylovis-201 is a good candidate for the therapeutic treatment of AD. Alzheimer's disease is the most common neurodegenerative disease, and its treatment is lacking. In this work, we tested Amylovis-201, a naphthalene-derived compound, as a possible therapeutic candidate for the treatment of AD. For this purpose, we performed three experiments. In the first and third experiment, animals received a bilateral administration of streptozotocin and, starting 24 h after injection, a daily dose of Amylovis-201 (orally), for 17 days or for the whole time of the experiment respectively (28 days), after which learning and memory, as well as the number of hippocampal dentate gyrus cells, were assessed. In the second experiment, healthy animals received a single dose of Amylovis-201, 10 min or 5 h after the learning section to assess whether this substance could promote specific mechanisms involved in memory trace formation. Our data show that, administration of a single dose of Amylovis-201, 10 min after the end of training, but not at 5 h, produces a prolongation in memory duration, probably because it modulates specific mechanisms involved in memory trace consolidation. Furthermore, daily administration of Amylovis-201 to animals with bilateral intracerebroventricular injection of STZ produces a reduction in the loss of the hippocampus dentate gyrus cells and an improvement in spatial memory, probably because Amylovis-201 can interact with some of the protein kinases of the insulin signaling cascade, also involved in neural plasticity, and thereby halt or reverse some of the effects of STZ. Taking to account these results, Amylovis-201 is a good candidate for the therapeutic treatment of AD.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0006-8993 1872-6240
DOI:	10.1016/j.brainres.2024.148848